Whalley A S, Nguyen M L, Morrow W J
IDEC Pharmaceuticals Corporation, La Jolla, California.
Viral Immunol. 1991 Winter;4(4):201-13. doi: 10.1089/vim.1991.4.201.
In developing therapeutic reagents for the control of HIV infection, it is necessary to screen candidate products in vitro for their ability to reduce or neutralize viral infection. Although the current literature describes numerous neutralization assays, no universally accepted standards have been adopted. In this article, we briefly review the available neutralization assays and describe in detail the methods we have selected in our laboratory for the screening and characterization of reagents with potential anti-HIV properties. After evaluating many different technical protocols and experimental procedures, we have found the syncytium inhibition and syncytial focus assays to be particularly useful and have found p24 gag antigen production to be an excellent objective measure of HIV infection under a variety of conditions. These assays proved reproducible and sensitive and are suitable for use in the majority of laboratories.
在开发用于控制HIV感染的治疗性试剂时，有必要在体外筛选候选产品降低或中和病毒感染的能力。尽管目前的文献描述了众多中和试验，但尚未采用普遍接受的标准。在本文中，我们简要回顾了现有的中和试验，并详细描述了我们实验室选择的用于筛选和鉴定具有潜在抗HIV特性试剂的方法。在评估了许多不同的技术方案和实验程序后，我们发现合胞体抑制试验和多核巨细胞灶试验特别有用，并且发现在各种条件下，p24 gag抗原产生是HIV感染的一项出色客观指标。这些试验被证明具有可重复性和敏感性，适用于大多数实验室。
